Immune Checkpoint Inhibitor Islet Function Impairment Risk: Meta-Analysis of 31 RCTs

A meta-analysis of 31 randomized controlled trials with 15,417 cancer patients assessing the risk of islet function impairment from immune checkpoint inhibitors. The study, authored by Qi Hu and last updated in March 2026, pools risk ratios for outcomes including hyperglycemia, diabetes mellitus, and diabetic ketoacidosis. Results indicate a significantly increased risk of these adverse events, particularly with PD-1 inhibitors and in patients with non-small cell lung cancer.

Use Cases

• Quantifying the relative risk of hyperglycemia and diabetes based on pooled data from 15,417 patients.
• Comparing adverse event rates between different immune checkpoint inhibitor drug classes mentioned in the description.
• Identifying high-risk patient subgroups, such as those with NSCLC, based on the reported subgroup analysis.
• Assessing the severity of adverse events based on the reported risk ratios for grade 3-5 events.

Strengths

• Analysis is based on 31 randomized controlled trials, a robust study design for causal inference.
• Includes data from 15,417 patients, providing a substantial sample size for pooled estimates.
• Reports specific risk ratios with 95% confidence intervals for multiple outcomes and subgroups.

Limitations

• Row count and column-level documentation are absent; field semantics must be inferred after download.
• The dataset is a 23.1 KB DOCX file, suggesting it contains summary tables rather than the underlying patient-level data.

Provenance

Source

Systematic review and meta-analysis conducted by Qi Hu, published on figshare.

Collection Method

Data was gathered by searching multiple databases (PubMed, Embase, etc.) for RCTs up to October 24, 2024, following PICOS principles.

Time Range

Studies from database inception to October 24, 2024.

Freshness

Last updated 2026-03-19 06:49:59; freshness should be verified.